GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » Cyclically Adjusted PB Ratio

Scorpius Holdings (Scorpius Holdings) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Scorpius Holdings's current share price is $0.1083. Scorpius Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $36.62. Scorpius Holdings's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Scorpius Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Scorpius Holdings's highest Cyclically Adjusted PB Ratio was 0.11. The lowest was 0.01. And the median was 0.02.

SCPX's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.75
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Scorpius Holdings's adjusted book value per share data for the three months ended in Mar. 2024 was $0.794. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $36.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Scorpius Holdings Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Scorpius Holdings's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings Cyclically Adjusted PB Ratio Chart

Scorpius Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.05 0.01 0.01

Scorpius Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Competitive Comparison of Scorpius Holdings's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Scorpius Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scorpius Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Cyclically Adjusted PB Ratio falls into.



Scorpius Holdings Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Scorpius Holdings's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.1083/36.62
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scorpius Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Scorpius Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.794/131.7762*131.7762
=0.794

Current CPI (Mar. 2024) = 131.7762.

Scorpius Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 186.971 100.560 245.012
201409 160.168 100.428 210.164
201412 125.144 99.070 166.459
201503 159.663 99.621 211.198
201506 123.189 100.684 161.231
201509 82.358 100.392 108.105
201512 33.221 99.792 43.868
201603 22.479 100.470 29.483
201606 11.653 101.688 15.101
201609 21.863 101.861 28.284
201612 23.193 101.863 30.004
201703 24.410 102.862 31.272
201706 19.645 103.349 25.049
201709 15.426 104.136 19.521
201712 12.284 104.011 15.563
201803 9.439 105.290 11.813
201806 8.317 106.317 10.309
201809 7.437 106.507 9.201
201812 6.526 105.998 8.113
201903 5.467 107.251 6.717
201906 4.578 108.070 5.582
201909 3.411 108.329 4.149
201912 2.812 108.420 3.418
202003 2.428 108.902 2.938
202006 3.036 108.767 3.678
202009 5.418 109.815 6.502
202012 5.145 109.897 6.169
202103 5.462 111.754 6.441
202106 5.227 114.631 6.009
202109 4.967 115.734 5.655
202112 4.410 117.630 4.940
202203 4.126 121.301 4.482
202206 3.768 125.017 3.972
202209 3.298 125.227 3.470
202212 2.881 125.222 3.032
202303 2.378 127.348 2.461
202306 1.871 128.729 1.915
202309 1.392 129.860 1.413
202312 1.197 129.419 1.219
202403 0.794 131.776 0.794

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Scorpius Holdings  (AMEX:SCPX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Scorpius Holdings Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Scorpius Holdings (Scorpius Holdings) Business Description

Traded in Other Exchanges
Address
627 Davis Drive, Suite 300, Morrisville, NC, USA, 27560
NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has categories: Oncology, immunology and molecular biology.
Executives
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf director, officer: Chief Executive Officer 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii director C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander officer: CFO/Corp Secy 801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan director
Robert James Jakobs officer: VP Finance/Controller/Secty PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins officer: Chief Scientific Officer 15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar officer: VP of Finance and Controller C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov director 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech officer: Chief Financial Officer C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc 10 percent owner 1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber officer: Vice President of Research 100 EUROPA DRIVE, CHAPEL HILL NC 27517

Scorpius Holdings (Scorpius Holdings) Headlines

From GuruFocus

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

By GuruFocusNews GuruFocusNews 12-21-2021